RhumbLine Advisers’s Taysha Gene Therapies TSHA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $539K | Buy |
233,256
+27,794
| +14% | +$64.2K | ﹤0.01% | 2643 |
|
|
2025
Q1 | $286K | Buy |
205,462
+13,383
| +7% | +$18.6K | ﹤0.01% | 2917 |
|
|
2024
Q4 | $332K | Buy |
192,079
+5,831
| +3% | +$10.1K | ﹤0.01% | 2931 |
|
|
2024
Q3 | $374K | Buy |
186,248
+1,964
| +1% | +$3.95K | ﹤0.01% | 2900 |
|
|
2024
Q2 | $413K | Buy |
+184,284
| New | +$413K | ﹤0.01% | 2809 |
|
|
2022
Q2 | – | Sell |
-22,389
| Closed | -$146K | – | 3237 |
|
|
2022
Q1 | $146K | Buy |
22,389
+2,619
| +13% | +$17.1K | ﹤0.01% | 2825 |
|
|
2021
Q4 | $230K | Sell |
19,770
-361
| -2% | -$4.2K | ﹤0.01% | 2796 |
|
|
2021
Q3 | $375K | Buy |
20,131
+1,460
| +8% | +$27.2K | ﹤0.01% | 2678 |
|
|
2021
Q2 | $396K | Buy |
+18,671
| New | +$396K | ﹤0.01% | 2663 |
|